A Phase I, Open Label, Single-Dose, Randomized, Four-Way Crossover Study to Compare the Pharmacokinetics of NP101 (Sumatriptan Iontophoretic Transdermal Patch) With an Oral Formulation of Imitrex [sumatriptan] in Migraine Subjects During an Acute Migraine Attack and a Non-Migraine Period.
Phase of Trial: Phase I
Latest Information Update: 25 Apr 2012
At a glance
- Drugs Sumatriptan (Primary) ; Sumatriptan (Primary)
- Indications Migraine
- Focus Pharmacokinetics
- 25 Apr 2012 Actual patient number (23) added as reported by ClinicalTrials.gov.
- 12 Feb 2010 Actual end date (Sep 2009) added as reported by ClinicalTrials.gov.
- 12 Feb 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.